arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Intellia Therapeutics, Inc.

NTLA
$11.95 ▲ +0.42 (+3.64%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
47 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Intellia Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B
Dividend Yield
Revenue Growth -9.5%
Op. Margin None
ROIC -12.8%
FCF / Share $-0.99
Trailing P/E
Price / Book 2.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$15.05M
↓ -9.5%
Net Income Profit after all expenses
$-96.23M
↑ +15.8%
Operating Margin Operating profit as % of sales
-428.9%
↓ -8.8%
FCF / Share Free cash flow per share
$-0.99
↑ +31.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
14
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters